Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating

Moomoo NewsFeb 7 07:33 ET

Piper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)

TipRanksFeb 7 06:54 ET

ACELYRIN, INC. (SLRN) Receives a Buy From Wells Fargo

TipRanksFeb 7 06:41 ET

Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsJan 8 09:32 ET

A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $5 to $20

Moomoo NewsJan 8 08:03 ET

Cautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab's Efficacy and Dosing

TipRanksJan 8 05:56 ET

Acelyrin Analyst Ratings

BenzingaJan 8 05:37 ET

ACELYRIN Is Maintained at Neutral by Citigroup

Dow JonesJan 7 15:09 ET

Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3

BenzingaJan 7 14:59 ET

Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $13

Moomoo NewsJan 7 06:38 ET

Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsJan 7 06:38 ET

H.C. Wainwright Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6

Moomoo NewsJan 7 06:38 ET

ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.

Dow JonesJan 7 06:34 ET

ACELYRIN, INC.'s Lonigutamab Program: Balancing Innovation and Uncertainty With a Hold Rating

TipRanksJan 7 06:32 ET

Acelyrin Analyst Ratings

BenzingaJan 7 06:20 ET

Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating

TipRanksJan 7 06:11 ET

Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5

Moomoo NewsDec 20, 2024 13:31 ET

Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5

Moomoo NewsDec 19, 2024 05:36 ET

Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections

TipRanksDec 19, 2024 05:27 ET

ACELYRIN Is Maintained at Overweight by Wells Fargo

Dow JonesDec 11, 2024 10:15 ET